High-dose chemotherapy with autologous stem cell support in patients with responding stage IV breast cancer

Bone Marrow Transplantation

Volumn 22, Issue 5, 1998, Pages 445-448

  Ljungman, P ^a   Bjorkstrand B ^a   Fornander, T ^a   Hoglund M ^b   Juliusson, G ^b   Lindman, H ^c   Malmstrom A ^c   Rotstein, S ^d   Soderberg M ^e   Wilking, N ^a   Villman, K ^f   Bergh, J ^c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^d DANDERYD HOSPITAL   (Sweden)

^e Karlstad Hospital   (Sweden)

^f ÖREBRO MEDICAL CENTRE HOSPITAL   (Sweden)

Author keywords

Autologous SCT; Breast cancer; Stage IV

Indexed keywords

CARBOPLATIN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; THIOTEPA;

ADULT; ARTICLE; BREAST CANCER; CANCER SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL;

EID: 0031667491     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701367     Document Type: Article

References (17)

1. Ayash L, Wheeler C, Fairclough D et al. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol 1995; 13: 2043-2049.
2. Antman K, Ayash L, Elias A et al. A phase II study of high-dose cyclophosphamide, thiotepa. and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy: see comments. J Clin Oncol 1992; 10: 102-110.
3. Peters W, Shpall E, Jones R et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 1988; 6: 1368-1376.
4. Bensinger W, Schiffman K, Holmberg L et al. High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer. Bone Marrow Transplant 1997; 19 :1183-1189.
5. Antman K, Rowlings P, Vaughan W et al. High-dose chemotherapy with autologous stem-cell support for breast cancer in North America. J Clin Oncol 1997; 15: 1870-1879.
6. Bezwoda W, Seymour L, Dansey R. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995; 13: 2483-2489.
7. Bergh J. Dose intensity in patients with metastatic breast cancer - time for novel thoughts? Ann Oncol 1997; 8: 109-110.
8. Peters WP, Ross M, Vredenburgh JJ et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132-1143.
9. Lindman H, Wiklund T, Holte H et al. A feasibility study on mobilisation of peripheral blood stem cells in human breast cancer patients by a modified FEC regimen supported by G-CSF (filgrastim) in the adjuvant setting. Acta Oncologica 1998 (submitted).
10. Somlo G, Donoshow J, Forman S et al. High-dose doxoruhicin, etoposide, and cyclophosphamide with stem cell rein-fusion in patients with metastatic or high-risk primary breast cancer. Cancer 1994; 73: 1678-1685.
11. Stemmer S, Cagnoni P, Shpall E et al. High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor cell support: a phase I trial. J Clin Oncol 1996; 14: 1463-1472.
12. Ayash LJ, Elias A, Wheeler C et al. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study. J Clin Oncol 1994; 12: 37-44.
13. Bitran J, Samuels B, Klein L et al. Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yield prolonged survival in stage IV breast cancer. Bone Marrow Transplant 1996; 17: 157-162.
14. Brugger W, Bross K, Glatt M et al. Mobilization of tumor cells and hematopoietic progenitor cells in peripheral blood of patients with solid tumors. Blood 1994; 83: 636-640.
15. Shpall EJ, Jones RB, Bearman SI et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol 1994; 12: 28-36.
16. + hematopoietic progenitor cells for transplantation. Stem Cells (Dayt) 1993; 3: 48-49.
17. Ljungman P, Björkstrand B, Gahrton G et al. Treatment of breast cancer with high dose chemotherapy in combination with autologous stem cell support. Läkartidningen 1994; 92: 849-853.